Immunotherapy: Open Access
Open Access

Jonas Henriksen

Publications

• Commentary
  Targeting Monocytes with TLR7 Ligands as a Novel Opportunity in Immuno-Oncology
  Author(s): Simon S Jensen, Ladan Parhamifar, Jonas Henriksen and Thomas L Andresen Simon S Jensen, Ladan Parhamifar, Jonas Henriksen and Thomas L Andresen
  
  Cancer immunotherapy has for the last decade been one of the fastest developing therapeutic areas in oncology with promising clinical benefits, supporting a role of immunotherapy as a cornerstone in future cancer treatment in combination with existing treatments. Treatment of early stage cancers today is very efficient due to refined surgery, chemotherapy, radiation and use of therapeutic antibodies, but a large group of patients in particular with late stage and metastatic disease have poor prognosis due to lack of efficient treatment options. Thus, there is an urgent need to develop new technologies to provide more efficient treatment of late stage cancers, focused towards cure of these patients. One approach that may lead to better treatment is utilising the immune system of these patients, in order to generate durable anti-tumor memory immune responses. One strategy to boost the i.. View More»
  DOI: 10.4172/2471-9552.1000114

  Abstract PDF

Relevant Topics